When.com Web Search

  1. Ads

    related to: non statin cholesterol lowering drug class examples

Search results

  1. Results From The WOW.Com Content Network
  2. Lipid-lowering agent - Wikipedia

    en.wikipedia.org/wiki/Lipid-lowering_agent

    Level of the good cholesterol HDL is also increased. Fibrates may decrease LDL, though generally to a lesser degree than statins. Similar to statins, the risk of muscle damage exists. Nicotinic acid, like fibrates, is also well suited for lowering triglycerides by 20–50%. It may also lower LDL by 5–25% and increase HDL by 15–35%.

  3. Non-statin cholesterol-lowering drugs may help reduce liver ...

    www.aol.com/non-statin-cholesterol-lowering...

    Out of five non-statin cholesterol-lowering drug classes, only cholesterol absorption inhibitors are found to reduce the risk of liver cancer, a new study has found. The link between liver cancer ...

  4. Cardiovascular agents - Wikipedia

    en.wikipedia.org/wiki/Cardiovascular_agents

    Examples of this drug class are atorvastatin, rosuvastatin, fluvastatin, simvastatin, pravastatin and lovastatin. Most efficacious in lowering LDL-C levels, statins block the action of HMG-CoA reductase through competitive inhibition. [18]

  5. Bempedoic acid, which was approved in 2020 by the Food and Drug Administration, is not as effective as statins, which are considered the gold standard in treating high cholesterol. However, many ...

  6. ATC code C10 - Wikipedia

    en.wikipedia.org/wiki/ATC_code_C10

    ATC code C10 Lipid modifying agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.

  7. Cholesterol absorption inhibitor - Wikipedia

    en.wikipedia.org/wiki/Cholesterol_absorption...

    Cholesterol absorption inhibitors are known to have a synergistic effect when combined a class of antihyperlipidemics called statins, to achieve an overall serum cholesterol target. For statin-resistant or statin-sensitive populations that are characterized by low one-year compliance rates, such a combination therapy is proving to be especially ...